ERBB2 and breast cancer: Particularly, the level of ERK5 expression inversely correlates with relapse-free survival (RFS) and distant metastasis-free survival (DMFS) in the basal-like, including TNBC and HER2+ BC patients [95] who received chemotherapy [139].